title: Bortezomib and melphalan conditioning increases the rate of complete response and MRD negativity for patients with multiple myeloma undergoing single autologous stem cell transplant.
authors.affiliation: a Tom Baker Cancer Center , Department of Medical Oncology and Hematology , Calgary , AB , Canada .
authors.forename: Victor H
authors.initials: VH
authors.lastname: Jimenez-Zepeda
authors.affiliation: a Tom Baker Cancer Center , Department of Medical Oncology and Hematology , Calgary , AB , Canada .
authors.forename: Peter
authors.initials: P
authors.lastname: Duggan
authors.affiliation: a Tom Baker Cancer Center , Department of Medical Oncology and Hematology , Calgary , AB , Canada .
authors.forename: Paola
authors.initials: P
authors.lastname: Neri
authors.affiliation: a Tom Baker Cancer Center , Department of Medical Oncology and Hematology , Calgary , AB , Canada .
authors.forename: Ahsan
authors.initials: A
authors.lastname: Chaudhry
authors.affiliation: a Tom Baker Cancer Center , Department of Medical Oncology and Hematology , Calgary , AB , Canada .
authors.forename: Karen
authors.initials: K
authors.lastname: Murray
authors.affiliation: a Tom Baker Cancer Center , Department of Medical Oncology and Hematology , Calgary , AB , Canada .
authors.forename: Marcia
authors.initials: M
authors.lastname: Culham
authors.affiliation: b Calgary Lab Services , Calgary , AB , Canada , and.
authors.forename: Joanne
authors.initials: J
authors.lastname: Luider
authors.affiliation: c Department of Pathology and Laboratory Medicine , Foothills Medical Center , Calgary , AB , Canada.
authors.forename: Thomas
authors.initials: T
authors.lastname: Fourie
authors.affiliation: c Department of Pathology and Laboratory Medicine , Foothills Medical Center , Calgary , AB , Canada.
authors.forename: Fariborz
authors.initials: F
authors.lastname: Rashid-Kolvear
authors.affiliation: a Tom Baker Cancer Center , Department of Medical Oncology and Hematology , Calgary , AB , Canada .
authors.forename: Nizar J
authors.initials: NJ
authors.lastname: Bahlis
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000069286:Bortezomib / Q000008:administration & dosage; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008558:Melphalan / Q000008:administration & dosage; D009101:Multiple Myeloma / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy*; D018365:Neoplasm, Residual / Q000473:pathology*; D019172:Transplantation Conditioning; D016896:Treatment Outcome
chemical_list: D000069286:Bortezomib; D008558:Melphalan